Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138Jort J van der Schans, Ziyu Wang, Jennemiek van Arkel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of ApoptosisLisa C Holthof, Jort J van der Schans, Afroditi Katsarou, et al.Expert Review of Clinical Immunology|February 22, 2018
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experienceKristine A Frerichs, Noemi Anna Nagy, Pieter L Lindenbergh, et al.Biomolecules|December 30, 2025
Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone DiseaseJiaxian Wang, Thomas Baardemans, Ricardo de Matos Simoes, et al.Haematologica|August 3, 2019
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartmentBarbara Depreter, Karin E Weening, Karl Vandepoele, et al.Nature Biomedical Engineering|August 8, 2022
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cellsSjoukje J C van der Stegen, Pieter L Lindenbergh, Roseanna M Petrovic, et al.Haematologica|February 10, 2016
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaEsther Drent, Richard W J Groen, Willy A Noort, et al.Science Translational Medicine|December 8, 2021
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistenceAfroditi Katsarou, Maria Sjöstrand, Jyoti Naik, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?Sonia Guedan, Maik Luu, Delphine Ammar, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.Pageof 5